SGLT2 Inhibitor Updates

In the latest results, dapagliflozin improved control when glimepiride was added. Through 48 weeks, dapagliflozin plus glimepiride reduced HbA1c levels by 0.37% to 0.70% compared with placebo plus glimepiride. There were also sustained reductions in fasting plasma glucose and post-prandial glucose and small reductions in total body weight (1.3 to 3.6 pounds). Rates of genital infections and hypoglycemic events were higher in the dapagliflozin groups. IDF, World Diabetes Congress, Dubai